When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.
C. Daniel Mullins, PhD
Advertisement
Articles by C. Daniel Mullins, PhD
Among commercially insured patients treated with linezolid or vancomycin following cSSSI-related hospitalization, linezolid was associated with significantly lower rehospitalization rates and total direct medical costs.
Advertisement
Latest Updated Articles
- Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin
Published: December 13th 2013 | Updated:
- Payers' Views on the Heterogeneity of Treatment Effect in Oncology
Published: June 22nd 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5
